MT-ND4L
ENSG00000212907
Target class
Enzyme
Chromosome
Mitochondrial
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Limited
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- MT-ND4L
- Gene name
- Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L
- Gene symbol
- MT-ND4L
- Previous gene symbols
- MTND4L
- Protein name
- NADH-ubiquinone oxidoreductase chain 4L (EC 7.1.1.2) (NADH dehydrogenase subunit 4L) (ND4L)
- ND4L
- NAD4L
- Gene biotype
- Protein coding
- Gene family
- NADH:ubiquinone oxidoreductase core subunits|Mitochondrially encoded protein coding genes
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 33,454.5
- Tissue specificity (Gini)
- 0.249
- Tissue specificity (tau)
- 0.531
- KEGG gene identifiers
- hsa:4539
- Reactome pathways
- R-HSA-5419276
- Protein interaction confidence
- 0.930149
- Protein interaction partners
- 87
- End position
- 10766
- Start position
- 10470
- Chromosome
- Mitochondrial
- Strand
- Forward
- Mitochondrion inner membrane
- Multi-pass membrane protein .
- Centrosome
- Cytosol
- Mitochondria
- Tissue specificity (tau)
- 0.531273
- Expression inequality (Gini)
- 0.248864
Expression in transcripts per million
- Heart - Left Ventricle
- 33,454.5
- Heart - Atrial Appendage
- 27,144.2
- Brain - Cortex
- 26,160.5
- Liver
- 26,085.5
- Brain - Caudate (basal ganglia)
- 25,756.8
Expression in transcripts per million
- Heart - Left Ventricle33,454.5
- Heart - Atrial Appendage27,144.2
- Brain - Cortex26,160.5
- Liver26,085.5
- Brain - Caudate (basal ganglia)25,756.8
- Brain - Putamen (basal ganglia)25,598.9
- Brain - Hippocampus25,558.6
- Brain - Hypothalamus24,747.7
- Adrenal Gland24,185
- Brain - Substantia nigra24,134
- Brain - Anterior cingulate cortex (BA24)23,311.7
- Brain - Amygdala23,020.7
- Brain - Nucleus accumbens (basal ganglia)23,018.5
- Kidney - Cortex21,321
- Brain - Spinal cord (cervical c-1)21,258.7
- Stomach19,509.8
- Muscle - Skeletal19,334.3
- Kidney - Medulla19,237.3
- Brain - Cerebellum18,732.4
- Brain - Frontal Cortex (BA9)18,701.6
- Esophagus - Muscularis18,454
- Colon - Transverse18,081.4
- Prostate18,023.4
- Esophagus - Gastroesophageal Junction17,916.2
- Adipose - Visceral (Omentum)17,101.5
And 29 more, listed on the interactive page.
- GO:0005739
- GO:0005743
- GO:0045271
Molecular functions
- GO:0008137
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor